Literature DB >> 29920138

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.

Antonio C Wolff1, M Elizabeth Hale Hammond1, Kimberly H Allison1, Brittany E Harvey1, Lisa M McShane1, Mitchell Dowsett1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29920138     DOI： 10.1200/JOP.18.00206

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  34 in total

1.  Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey.

Authors:  Pinkie Chambers; Kenneth K C Man; Vivian W Y Lui; Sheila Mpima; Paola Nasuti; Martin D Forster; Ian C K Wong
Journal:  JCO Oncol Pract       Date:  2020-03-11

2.  Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.

Authors:  Kathleen Fenn; Matthew Maurer; Shing M Lee; Katherine D Crew; Meghna S Trivedi; Melissa K Accordino; Dawn L Hershman; Kevin Kalinsky
Journal:  Clin Breast Cancer       Date:  2019-08-29       Impact factor: 3.225

3.  A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Authors:  J Veeraraghavan; C De Angelis; R Mao; T Wang; S Herrera; A C Pavlick; A Contreras; P Nuciforo; I A Mayer; A Forero; R Nanda; M P Goetz; J C Chang; A C Wolff; I E Krop; S A W Fuqua; A Prat; S G Hilsenbeck; B Weigelt; J S Reis-Filho; C Gutierrez; C K Osborne; M F Rimawi; R Schiff
Journal:  Ann Oncol       Date:  2019-06-01       Impact factor: 32.976

4.  HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.

Authors:  Marcia Edelweiss; Ana Paula Martins Sebastiao; Handy Oen; Mihaela Kracun; Rene Serrette; Dara S Ross
Journal:  Cancer Cytopathol       Date:  2019-09-22       Impact factor: 5.284

5.  DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER.

Authors:  C Kent Osborne; Rachel Schiff; Mothamar Rimawi
Journal:  Trans Am Clin Climatol Assoc       Date:  2020

6.  Prognostic and predictive parameters in breast pathology: a pathologist's primer.

Authors:  Kimberly H Allison
Journal:  Mod Pathol       Date:  2020-11-05       Impact factor: 7.842

7.  Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Authors:  K L Jhaveri; X V Wang; V Makker; S-W Luoh; E P Mitchell; J A Zwiebel; E Sharon; R J Gray; S Li; L M McShane; L V Rubinstein; D Patton; P M Williams; S R Hamilton; B A Conley; C L Arteaga; L N Harris; P J O'Dwyer; A P Chen; K T Flaherty
Journal:  Ann Oncol       Date:  2019-11-01       Impact factor: 32.976

8.  Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.

Authors:  Jennifer Zeng; Salvatore Piscuoglio; Gitika Aggarwal; Joanna Magda; Maria A Friedlander; Melissa Murray; Muzaffar Akram; Jorge S Reis-Filho; Britta Weigelt; Marcia Edelweiss
Journal:  Cancer Cytopathol       Date:  2019-12-28       Impact factor: 5.284

Review 9.  Genomics and the History of Precision Oncology.

Authors:  Deborah B Doroshow; James H Doroshow
Journal:  Surg Oncol Clin N Am       Date:  2019-10-29       Impact factor: 3.495

10.  Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.

Authors:  Alicia Okines; Tazia Irfan; Bernice Asare; Kabir Mohammed; Peter Osin; Ashutosh Nerurkar; Ian E Smith; Marina Parton; Alistair Ring; Stephen Johnston; Nicholas C Turner
Journal:  Breast Cancer Res Treat       Date:  2022-02-04       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.